India, July 1 -- Oncternal Therapeutics, Inc. (ONCT) announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc.
Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.
Ho'ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties.
Oncternal will also be eligible to receive up to $65.0 million in development, regulatory approval and sales m...